| pubmed-article:15027850 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15027850 | lifeskim:mentions | umls-concept:C1522538 | lld:lifeskim |
| pubmed-article:15027850 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:15027850 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:15027850 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:15027850 | lifeskim:mentions | umls-concept:C0205549 | lld:lifeskim |
| pubmed-article:15027850 | lifeskim:mentions | umls-concept:C1880355 | lld:lifeskim |
| pubmed-article:15027850 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:15027850 | lifeskim:mentions | umls-concept:C0249187 | lld:lifeskim |
| pubmed-article:15027850 | lifeskim:mentions | umls-concept:C1313841 | lld:lifeskim |
| pubmed-article:15027850 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:15027850 | pubmed:dateCreated | 2004-3-18 | lld:pubmed |
| pubmed-article:15027850 | pubmed:abstractText | From the discovery of competitive hexapeptide inhibitors, potent and selective HCV NS3 protease macrocyclic inhibitors have been identified. Structure-activity relationship studies were performed focusing on optimizing the N-terminal carbamate and the aromatic substituent on the (4R)-hydroxyproline moiety. Inhibitors meeting the potency criteria in the cell-based assay and with improved oral bioavailability in rats were identified. BILN 2061 was selected as the best compound, the first NS3 protease inhibitor reported with antiviral activity in man. | lld:pubmed |
| pubmed-article:15027850 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15027850 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15027850 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15027850 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15027850 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15027850 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15027850 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15027850 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15027850 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15027850 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15027850 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15027850 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:15027850 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:TsantrizosYou... | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:FaucherAnne-M... | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:BolgerGordonG | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:LamarreDaniel... | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:PoirierMartin... | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:GorysVidaV | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:HalmosTedT | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:Llinàs-Brunet... | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:BrochuChristi... | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:LiardFrancine... | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:GarneauMichel... | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:Grand-MaîtreC... | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:BaileyMurray... | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:FerlandJean... | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:GhiroEliseE | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:Lapeyre-Paque... | lld:pubmed |
| pubmed-article:15027850 | pubmed:author | pubmed-author:RhéaumeManonM | lld:pubmed |
| pubmed-article:15027850 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15027850 | pubmed:day | 25 | lld:pubmed |
| pubmed-article:15027850 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:15027850 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15027850 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15027850 | pubmed:pagination | 1605-8 | lld:pubmed |
| pubmed-article:15027850 | pubmed:meshHeading | pubmed-meshheading:15027850... | lld:pubmed |
| pubmed-article:15027850 | pubmed:meshHeading | pubmed-meshheading:15027850... | lld:pubmed |
| pubmed-article:15027850 | pubmed:meshHeading | pubmed-meshheading:15027850... | lld:pubmed |
| pubmed-article:15027850 | pubmed:meshHeading | pubmed-meshheading:15027850... | lld:pubmed |
| pubmed-article:15027850 | pubmed:meshHeading | pubmed-meshheading:15027850... | lld:pubmed |
| pubmed-article:15027850 | pubmed:meshHeading | pubmed-meshheading:15027850... | lld:pubmed |
| pubmed-article:15027850 | pubmed:meshHeading | pubmed-meshheading:15027850... | lld:pubmed |
| pubmed-article:15027850 | pubmed:meshHeading | pubmed-meshheading:15027850... | lld:pubmed |
| pubmed-article:15027850 | pubmed:meshHeading | pubmed-meshheading:15027850... | lld:pubmed |
| pubmed-article:15027850 | pubmed:meshHeading | pubmed-meshheading:15027850... | lld:pubmed |
| pubmed-article:15027850 | pubmed:meshHeading | pubmed-meshheading:15027850... | lld:pubmed |
| pubmed-article:15027850 | pubmed:meshHeading | pubmed-meshheading:15027850... | lld:pubmed |
| pubmed-article:15027850 | pubmed:meshHeading | pubmed-meshheading:15027850... | lld:pubmed |
| pubmed-article:15027850 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15027850 | pubmed:articleTitle | Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. | lld:pubmed |
| pubmed-article:15027850 | pubmed:affiliation | Department of Chemistry, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval, Québec H7S 2G5, Canada. mllinas@lav.boehringer-ingelheim.com | lld:pubmed |
| pubmed-article:15027850 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:15027850 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15027850 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15027850 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15027850 | lld:pubmed |
